HistoAtlas: A Pan-Cancer Morphology Atlas Linking Histomics to Molecular Programs and Clinical Outcomes
Abstract
We present HistoAtlas, a pan-cancer computational atlas that extracts 38 interpretable histomic features from 6,745 diagnostic H&E slides across 21 TCGA cancer types and systematically links every feature to survival, gene expression, somatic mutations, and immune subtypes. All associations are covariate-adjusted, multiple-testing corrected, and classified into evidence-strength tiers. The atlas recovers known biology, from immune infiltration and prognosis to proliferation and kinase signaling, while uncovering compartment-specific immune signals and morphological subtypes with divergent outcomes. Every result is spatially traceable to tissue compartments and individual cells, statistically calibrated, and openly queryable. HistoAtlas enables systematic, large-scale biomarker discovery from routine H&E without specialized staining or sequencing. Data and an interactive web atlas are freely available at https://histoatlas.com .
Figures & tables
| No. | Feature | Formula / definition | Unit |
|---|---|---|---|
| (A) Tissue composition | |||
| 1 | Tumor area fraction | fraction | |
| 2 | Stroma area fraction | fraction | |
| 3 | Normal epithelium area fraction † | fraction | |
| 4 | Eosinophil-neutrophil ratio (peritumoral) | ratio | |
| (B) Cell densities | |||
| ID | Axis | Claim | Evid. | Key statistic | Cancer | References |
|---|---|---|---|---|---|---|
| 1.1 | Immune | Higher intratumoral TIL density better OS in BRCA | WE | HR = 0.72 (0.60–0.88), adj. | BRCA | ( 35 , 60 , 27 ) |
| 1.2 | Immune | Higher intratumoral TIL density better OS pan-cancer | WE | HR = 0.87 (0.81–0.93), adj. | PAN | ( 35 , 37 ) |
| 1.3 | Immune | Stromal lymphocyte density shows weaker protective effect than intratumoral pan-cancer | SUP | HR = 0.89 (0.83–0.97), adj. | PAN | ( 27 ) |
| 1.4 | Immune | Compartment-specific prognostic strength: intratumoral stromal | NP | IT HR = 0.87 vs S HR = 0.89, adj. | PAN | ( 35 ) |
| 1.5 | Immune | Immune desert fraction predicts worse OS in LIHC | SUP | HR = 1.29 (1.12–1.48) | LIHC | ( 36 ) |
| 1.6 | Immune | Deep intratumoral lymphocyte fraction protective in HNSC | SUP | HR = 0.79 (0.68–0.91) | HNSC | ( 37 ) |
| Abbreviation | Full name | slides | Status |
| ACC | Adrenocortical carcinoma | 227 | Included |
| BLCA | Bladder urothelial carcinoma | 417 | Included |
| BRCA | Breast invasive carcinoma | Included | |
| CESC | Cervical squamous cell carcinoma | 279 | Included |
| CHOL | Cholangiocarcinoma | 38 | Included |
| COAD | Colon adenocarcinoma | 441 | Included |
| Category | Genes |
|---|---|
| Immune / checkpoint (36) | CD274 (PD-L1), PDCD1 (PD-1), PDCD1LG2 (PD-L2), CTLA4, LAG3, TIGIT, HAVCR2 (TIM-3), IDO1, CD8A, CD8B, CD4, CD3D, CD3E, FOXP3, CD19, CD79A, MS4A1 (CD20), CD14, CD68, CD163, CD40, CD80, CD86, ITGAM, NKG7, IFNG, GZMA, GZMB, PRF1, TNF, IL6, IL10, IL2, CXCL9, CXCL10, TGFB1 |
| Proliferation / cell cycle (15) | MKI67, TOP2A, PCNA, CCNB1, CCND1, CCNE1, CDK1, CDK2, CDK4, CDK6, PLK1, AURKA, BIRC5, MCM2, E2F1 |
| EMT / invasion / stemness (15) | CDH1, CDH2, VIM, SNAI1, SNAI2, ZEB1, ZEB2, TWIST1, FN1, ACTA2, ALDH1A1, CD44, SOX2, NANOG, PROM1 |
| Apoptosis / DNA damage (19) | TP53, BCL2, BCL2L1, MCL1, BAX, CASP3, CASP8, FAS, BRCA1, BRCA2, ATM, CHEK1, CHEK2, RAD51, PARP1, MLH1, MSH2, MSH6, CDKN2A |
| Signaling / oncogenes (27) | EGFR, ERBB2 (HER2), MET, KRAS, NRAS, HRAS, BRAF, NF1, PIK3CA, PTEN, AKT1, MTOR, NOTCH1, FBXW7, CTNNB1, APC, SMAD4, RB1, MYC, ALK, RET, FGFR1, FGFR2, FGFR3, KIT, PDGFRA, JAK2 |
| Hormone receptors (3) | ESR1, PGR, AR |
| MSigDB Hallmark pathway | Biological category |
|---|---|
| HALLMARK_ADIPOGENESIS | Metabolic |
| HALLMARK_ALLOGRAFT_REJECTION | Immune |
| HALLMARK_ANDROGEN_RESPONSE | Hormonal |
| HALLMARK_ANGIOGENESIS | Development |
| HALLMARK_APICAL_JUNCTION | Cellular component |
| HALLMARK_APICAL_SURFACE | Cellular component |
| Analysis type | Family definition | Typical family size |
|---|---|---|
| Survival (Cox) | Cancer type endpoint model | 36–38 |
| Survival (RMST) | Cancer type endpoint model | 36–38 |
| Molecular correlations | Cancer type target set method model | 133–293 |
| Categorical associations | Cancer type variable test type model | 36–38 |
| Cluster survival (Cox) | Cluster level analysis type cancer endpoint model | 10–69 |
| Cluster survival (log-rank) | Cluster level analysis type cancer endpoint | 10–69 |
| Cancer type | models | Pass (%) | Warn (%) | Fail (%) |
|---|---|---|---|---|
| ACC | 114 | 112 (98) | 2 (2) | 0 (0) |
| BLCA | 152 | 145 (95) | 7 (5) | 0 (0) |
| BRCA | 152 | 141 (93) | 9 (6) | 2 (1) |
| CESC | 152 | 135 (89) | 8 (5) | 9 (6) |
| CHOL | 114 | 109 (96) | 5 (4) | 0 (0) |
| COAD | 152 | 145 (95) | 4 (3) | 3 (2) |
| Cancer type | (unadjusted) | (adjusted) | MICE used |
|---|---|---|---|
| ACC | 55 | 55 | Yes |
| BLCA | 348 | 348 | Yes |
| BRCA | 960 | 960 | Yes |
| CESC | 261 | 261 | No ‡ |
| CHOL | 36 | 36 | No |
| COAD | 413 | 413 | Yes |
| Cancer type | Horizon (days) | Rationale |
|---|---|---|
| PAAD | 730 (2 yr) | Aggressive; short median survival |
| MESO | 730 (2 yr) | Aggressive; short median survival |
| THCA | 1825 (5 yr) | Indolent; long median survival |
| PRAD | 1825 (5 yr) | Indolent; long median survival |
| All others | 1095 (3 yr) | Default |
| No. | Feature | Min | Max | Mean | Std | Median | IQR |
| (A) Tissue composition | |||||||
| 1 | Tumor area fraction | 0.04 | 0.93 | 0.45 | 0.20 | 0.43 | 0.29–0.60 |
| 2 | Stroma area fraction | 0.02 | 0.92 | 0.45 | 0.22 | 0.46 | 0.28–0.62 |
| 4 | Eos/neu ratio (peritumoral) | 0.00 | 2.70 | 0.40 | 0.47 | 0.22 | 0.09–0.52 |
| (B) Cell densities (log scale) | |||||||
| 5 | Cancer cell density (IT) | 5.15 | 9.39 | 8.37 | 0.58 | 8.47 | 8.10–8.75 |
| Cancer | Expression | CNV | Pathway | Immune | Total | % | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACC | 52 | 370/ | 0/ | 139/ | 62/ | 480 | 571/ | 2.2 | ||||
| BLCA | 344 | / | 421/ | / | 299/ | 480 | / | 24.7 | ||||
| BRCA | 953 | / | / | / | 346/ | 492 | / | 47.7 | ||||
| CESC | 259 | / | 1/ | 444/ | 83/ | 240 | / | 12.3 | ||||
| CHOL | 36 | 168/ | 0/ | 0/ | 0 | 39/ | 480 | 207/ | 1.0 | |||
| COAD | 405 | / | 429/ | / | 238/ | 480 | / | 18.4 | ||||
| Endpoint | Available pairs | Replicated ( ) | Replication rate |
|---|---|---|---|
| OS (reference) | 60 | 60 | 100% |
| DSS | 59 | 37 | 62.7% |
| PFS | 60 | 32 | 53.3% |
| DSS & PFS | 59 | 29 | 49.2% a |
Computational Pathology
Computational pathology uses algorithms to analyze digitized tissue images for diagnosis, prognosis, biomarker discovery, and clinical decision support.
See all 271 papers